Walleye Capital LLC Makes New $587,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Walleye Capital LLC acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 193,709 shares of the company's stock, valued at approximately $587,000. Walleye Capital LLC owned approximately 0.27% of Zentalis Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $39,000. Cerity Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $40,000. Ieq Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $46,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $53,000. Finally, Meriwether Wealth & Planning LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $66,000.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.47 on Wednesday. The business has a 50-day moving average of $1.72 and a two-hundred day moving average of $2.54. The company has a market capitalization of $105.56 million, a price-to-earnings ratio of -0.59 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $13.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. As a group, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka bought 60,000 shares of the business's stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company's stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ingmar Bruns bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

Analyst Upgrades and Downgrades

ZNTL has been the topic of a number of research reports. UBS Group reduced their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Wedbush reissued a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.